Latest Breaking News On - University of pennsylvania gene therapy program - Page 1 : comparemela.com

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomMichael amorosoAzercabtagene zapreleucelGene insertion programElimination programDevelopment expensesViral elimination programAquilo capital managementUniversity of pennsylvania gene therapy programDrug administrationTherapeutics incPrecision biosciences incPrecision biosciencesChief executive officerPrevail therapeuticsOwned portfolio

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMichael amorosoJamesm wilsonUniversity of pennsylvania gene therapy programDrug administrationEuropean commissionPrecision biosciences incPrecision biosciencesFast trackOrnithine transcarbamylaseRare pediatric diseaseOrphan drugChief executive officerGene therapy programPrivate securities litigation reform act

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months.

United statesUniversity of pennsylvaniaMark formanMadeline nafusMike beyerWilliam chouUniversity of pennsylvania gene therapy programHealthcare communicationsExchange commissionUpenn gene therapy programSam brown incPassage bio incPassage bioGene therapyPrivate securities litigation reform actRisk factors

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial Of PBFT02 In FTD-GRN And Updated Strategic Priorities

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial Of PBFT02 In FTD-GRN And Updated Strategic Priorities
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity of pennsylvaniaMadeline nafusMark formanWilliam chouMike beyerSam brown incExchange commissionPassage bio incUpenn gene therapy programUniversity of pennsylvania gene therapy programHealthcare communicationsPassage bioGene therapyPrivate securities litigation reform actRisk factors

Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE

- OTC Deficiency Gene Insertion Program, ECUR-506, Receives Clearance from Australian Therapeutic Goods Administration for Phase 1/2 Study .

Jamesm wilsonMichael amorosoJeff smithUniversity of pennsylvania gene therapy programPrecision biosciences incEuropean society of gene cell therapyAustralian therapeutic goods administrationPrecision biosciencesOrnithine transcarbamylaseTrial applicationChief executive officerEuropean societyCell therapyAnnual congressChief research officerGene therapy program